Literature DB >> 21928835

Structural insights into the activation and inhibition of histo-aspartic protease from Plasmodium falciparum.

Prasenjit Bhaumik1, Huogen Xiao, Koushi Hidaka, Alla Gustchina, Yoshiaki Kiso, Rickey Y Yada, Alexander Wlodawer.   

Abstract

Histo-aspartic protease (HAP) from Plasmodium falciparum is a promising target for the development of novel antimalarial drugs. The sequence of HAP is highly similar to those of pepsin-like aspartic proteases, but one of the two catalytic aspartates, Asp32, is replaced with histidine. Crystal structures of the truncated zymogen of HAP and of the complex of the mature enzyme with inhibitor KNI-10395 have been determined at 2.1 and 2.5 Å resolution, respectively. As in other proplasmepsins, the propeptide of the zymogen interacts with the C-terminal domain of the enzyme, forcing the N- and C-terminal domains apart, thereby separating His32 and Asp215 and preventing formation of the mature active site. In the inhibitor complex, the enzyme forms a tight domain-swapped dimer, not previously seen in any aspartic proteases. The inhibitor is found in an unprecedented conformation resembling the letter U, stabilized by two intramolecular hydrogen bonds. Surprisingly, the location and conformation of the inhibitor are similar to those of the fragment of helix 2 comprising residues 34p-38p in the prosegments of the zymogens of gastric aspartic proteases; a corresponding helix assumes a vastly different orientation in proplasmepsins. Each inhibitor molecule is in contact with two molecules of HAP, interacting with the carboxylate group of the catalytic Asp215 of one HAP protomer through a water molecule, while also making a direct hydrogen bond to Glu278A' of the other protomer. A comparison of the shifts in the positions of the catalytic residues in the inhibitor complex presented here with those published previously gives further hints regarding the enzymatic mechanism of HAP.
© 2011 American Chemical Society

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21928835      PMCID: PMC3501826          DOI: 10.1021/bi201118z

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  51 in total

1.  Hemoglobin-degrading plasmepsin II is active as a monomer.

Authors:  Jun Liu; Eva S Istvan; Daniel E Goldberg
Journal:  J Biol Chem       Date:  2006-10-13       Impact factor: 5.157

2.  Additional interaction of allophenylnorstatine-containing tripeptidomimetics with malarial aspartic protease plasmepsin II.

Authors:  Koushi Hidaka; Tooru Kimura; Yumi Tsuchiya; Mami Kamiya; Adam J Ruben; Ernesto Freire; Yoshio Hayashi; Yoshiaki Kiso
Journal:  Bioorg Med Chem Lett       Date:  2007-03-21       Impact factor: 2.823

Review 3.  The structure and function of the aspartic proteinases.

Authors:  D R Davies
Journal:  Annu Rev Biophys Biophys Chem       Date:  1990

4.  On the size of the active site in proteases. I. Papain.

Authors:  I Schechter; A Berger
Journal:  Biochem Biophys Res Commun       Date:  1967-04-20       Impact factor: 3.575

5.  Structural characterization of activation 'intermediate 2' on the pathway to human gastricsin.

Authors:  A R Khan; M M Cherney; N I Tarasova; M N James
Journal:  Nat Struct Biol       Date:  1997-12

6.  Generation of hemoglobin peptides in the acidic digestive vacuole of Plasmodium falciparum implicates peptide transport in amino acid production.

Authors:  K A Kolakovich; I Y Gluzman; K L Duffin; D E Goldberg
Journal:  Mol Biochem Parasitol       Date:  1997-08       Impact factor: 1.759

7.  Functional insights into human HMG-CoA lyase from structures of Acyl-CoA-containing ternary complexes.

Authors:  Zhuji Fu; Jennifer A Runquist; Christa Montgomery; Henry M Miziorko; Jung-Ja P Kim
Journal:  J Biol Chem       Date:  2010-06-17       Impact factor: 5.157

Review 8.  Malaria.

Authors:  Brian M Greenwood; Kalifa Bojang; Christopher J M Whitty; Geoffrey A T Targett
Journal:  Lancet       Date:  2005 Apr 23-29       Impact factor: 79.321

9.  Small-sized human immunodeficiency virus type-1 protease inhibitors containing allophenylnorstatine to explore the S2' pocket.

Authors:  Koushi Hidaka; Tooru Kimura; Hamdy M Abdel-Rahman; Jeffrey-Tri Nguyen; Keith F McDaniel; William E Kohlbrenner; Akhteruzzaman Molla; Motoyasu Adachi; Taro Tamada; Ryota Kuroki; Noriko Katsuki; Yoshiaki Tanaka; Hikaru Matsumoto; Jun Wang; Yoshio Hayashi; Dale J Kempf; Yoshiaki Kiso
Journal:  J Med Chem       Date:  2009-12-10       Impact factor: 7.446

10.  Is histoaspartic protease a serine protease with a pepsin-like fold?

Authors:  N Andreeva; P Bogdanovich; I Kashparov; M Popov; M Stengach
Journal:  Proteins       Date:  2004-05-15
View more
  9 in total

Review 1.  Malaria parasite plasmepsins: More than just plain old degradative pepsins.

Authors:  Armiyaw S Nasamu; Alexander J Polino; Eva S Istvan; Daniel E Goldberg
Journal:  J Biol Chem       Date:  2020-05-04       Impact factor: 5.157

2.  Structures of plasmepsin II from Plasmodium falciparum in complex with two hydroxyethylamine-based inhibitors.

Authors:  Rosario Recacha; Janis Leitans; Inara Akopjana; Lilija Aprupe; Peteris Trapencieris; Kristaps Jaudzems; Aigars Jirgensons; Kaspars Tars
Journal:  Acta Crystallogr F Struct Biol Commun       Date:  2015-11-27       Impact factor: 1.056

3.  Crystal structure of Plasmodium falciparum proplasmepsin IV: the plasticity of proplasmepsins.

Authors:  Rosario Recacha; Kristaps Jaudzems; Inara Akopjana; Aigars Jirgensons; Kaspars Tars
Journal:  Acta Crystallogr F Struct Biol Commun       Date:  2016-08-09       Impact factor: 1.056

4.  Structures of plasmepsin X from Plasmodium falciparum reveal a novel inactivation mechanism of the zymogen and molecular basis for binding of inhibitors in mature enzyme.

Authors:  Pooja Kesari; Anuradha Deshmukh; Nikhil Pahelkar; Abhishek B Suryawanshi; Ishan Rathore; Vandana Mishra; John H Dupuis; Huogen Xiao; Alla Gustchina; Jan Abendroth; Mehdi Labaied; Rickey Y Yada; Alexander Wlodawer; Thomas E Edwards; Donald D Lorimer; Prasenjit Bhaumik
Journal:  Protein Sci       Date:  2022-02-05       Impact factor: 6.725

5.  Activation mechanism of plasmepsins, pepsin-like aspartic proteases from Plasmodium, follows a unique trans-activation pathway.

Authors:  Ishan Rathore; Vandana Mishra; Chandan Patel; Huogen Xiao; Alla Gustchina; Alexander Wlodawer; Rickey Y Yada; Prasenjit Bhaumik
Journal:  FEBS J       Date:  2020-05-26       Impact factor: 5.622

6.  Novel pseudo-aspartic peptidase from the midgut of the tick Rhipicephalus microplus.

Authors:  S Lu; L F Parizi; R J S Torquato; I S Vaz Junior; A S Tanaka
Journal:  Sci Rep       Date:  2019-01-24       Impact factor: 4.379

7.  Proteomic analysis of Plasmodium falciparum response to isocryptolepine derivative.

Authors:  Kitiya Rujimongkon; Mathirut Mungthin; Jumreang Tummatorn; Sumate Ampawong; Poom Adisakwattana; Usa Boonyuen; Onrapak Reamtong
Journal:  PLoS One       Date:  2019-08-08       Impact factor: 3.240

8.  Molecular modeling and prediction of binding mode and relative binding affinity of Art-Qui-OH with P. falciparum Histo-Aspartic Protease (HAP).

Authors:  Rajani Kanta Mahapatra; Niranjan Behera; Pradeep Kumar Naik
Journal:  Bioinformation       Date:  2012-09-11

9.  A Perspective on Thiazolidinone Scaffold Development as a New Therapeutic Strategy for Toxoplasmosis.

Authors:  Cristian Rocha-Roa; Diego Molina; Néstor Cardona
Journal:  Front Cell Infect Microbiol       Date:  2018-10-16       Impact factor: 5.293

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.